盐酸三烯四胺治疗肝豆状核变性:长期观察。

J Morita, M Yoshino, H Watari, I Yoshida, T Motohiro, F Yamashita, Y Okano, T Hashimoto
{"title":"盐酸三烯四胺治疗肝豆状核变性:长期观察。","authors":"J Morita,&nbsp;M Yoshino,&nbsp;H Watari,&nbsp;I Yoshida,&nbsp;T Motohiro,&nbsp;F Yamashita,&nbsp;Y Okano,&nbsp;T Hashimoto","doi":"10.1159/000457456","DOIUrl":null,"url":null,"abstract":"<p><p>Wilson's disease is an autosomal recessive disorder characterized by an accumulation of a toxic amount of copper in the body. Triethylene tetramine dihydrochloride (trientine, 2HCl) is a new chelating agent that may be effective in the removal of excess copper but long-term efficacy has not yet been investigated. Here we report the use of trientine over more than 8 years in 2 patients with Wilson's disease who could not tolerate D-penicillamine. We found no significant side effect, except a decreased serum iron concentration without clinical symptoms of anemia. In annual examinations at a steady state, the serum copper levels remained below 20 micrograms/100 ml. The 24-hour urinary copper excretion was less than that found using D-penicillamine, while the basal copper excretion, after 5 days abstinence from trientine, was maintained below 100 micrograms/day. Both hepatic and neurological manifestations except bulbar symptoms were recovered without any initial deterioration.</p>","PeriodicalId":11160,"journal":{"name":"Developmental pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000457456","citationCount":"12","resultStr":"{\"title\":\"Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.\",\"authors\":\"J Morita,&nbsp;M Yoshino,&nbsp;H Watari,&nbsp;I Yoshida,&nbsp;T Motohiro,&nbsp;F Yamashita,&nbsp;Y Okano,&nbsp;T Hashimoto\",\"doi\":\"10.1159/000457456\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Wilson's disease is an autosomal recessive disorder characterized by an accumulation of a toxic amount of copper in the body. Triethylene tetramine dihydrochloride (trientine, 2HCl) is a new chelating agent that may be effective in the removal of excess copper but long-term efficacy has not yet been investigated. Here we report the use of trientine over more than 8 years in 2 patients with Wilson's disease who could not tolerate D-penicillamine. We found no significant side effect, except a decreased serum iron concentration without clinical symptoms of anemia. In annual examinations at a steady state, the serum copper levels remained below 20 micrograms/100 ml. The 24-hour urinary copper excretion was less than that found using D-penicillamine, while the basal copper excretion, after 5 days abstinence from trientine, was maintained below 100 micrograms/day. Both hepatic and neurological manifestations except bulbar symptoms were recovered without any initial deterioration.</p>\",\"PeriodicalId\":11160,\"journal\":{\"name\":\"Developmental pharmacology and therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1992-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000457456\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Developmental pharmacology and therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000457456\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Developmental pharmacology and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000457456","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12

摘要

威尔逊氏病是一种常染色体隐性遗传病,其特征是体内铜的毒性积累。盐酸三烯四胺(trientine, 2HCl)是一种新型螯合剂,可能有效去除过量铜,但长期效果尚未研究。在这里,我们报告了2例不能耐受d -青霉胺的Wilson病患者使用曲恩汀超过8年。我们没有发现明显的副作用,除了血清铁浓度降低,没有贫血的临床症状。在稳定状态下的年度检查中,血清铜水平保持在20微克/100毫升以下,24小时尿铜排泄量低于使用d -青霉胺的尿铜排泄量,而停用曲安汀5天后,基础铜排泄量维持在100微克/天以下。除球茎症状外,肝脏和神经系统症状均恢复,未见任何初始恶化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.

Wilson's disease is an autosomal recessive disorder characterized by an accumulation of a toxic amount of copper in the body. Triethylene tetramine dihydrochloride (trientine, 2HCl) is a new chelating agent that may be effective in the removal of excess copper but long-term efficacy has not yet been investigated. Here we report the use of trientine over more than 8 years in 2 patients with Wilson's disease who could not tolerate D-penicillamine. We found no significant side effect, except a decreased serum iron concentration without clinical symptoms of anemia. In annual examinations at a steady state, the serum copper levels remained below 20 micrograms/100 ml. The 24-hour urinary copper excretion was less than that found using D-penicillamine, while the basal copper excretion, after 5 days abstinence from trientine, was maintained below 100 micrograms/day. Both hepatic and neurological manifestations except bulbar symptoms were recovered without any initial deterioration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Analgesia and sedation in neonatal intensive care using fentanyl by continuous infusion. Effect of calcium channel agonist (BAY K8644) on volatile anesthetic-mediated depression in neonatal rabbit papillary muscle. Mechanisms of increased sensitivity to A2 adenosine receptor stimulation in immature rabbit aortic rings. Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. Population pharmacokinetics of ceftizoxime in premature newborns.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1